Skip to main content
. 2022 Nov 16;35(12):e15958. doi: 10.1111/dth.15958

TABLE 7.

Summary of specific adverse events (N = 163)

Adverse events n (%) Treatment discontinuation n (%)
Eczema 2 (1.2%) 2 (1.2%)
Injection site reaction 1 (0.6%) 0 (0.0%)
Pancytopenia 1 (0.6%) 1 (0.6%)
Pruritus 1 (0.6%) 0 (0.0%)
Seborrheic dermatitis 1 (0.6%) 0 (0.0%)
Dermatophyte infection 1 (0.6%) 1 (0.6%)
Upper respiratory tract infection 1 (0.6%) 0 (0.0%)
Worsening PASI score 5 (3.1%) a
a

No specified detail.